Literature DB >> 27776907

Sensitivity and Specificity of Metal Ion Levels in Predicting "Pseudotumors" due to Taper Corrosion in Patients With Dual Taper Modular Total Hip Arthroplasty.

Young-Min Kwon1, Tsung-Yuan Tsai1, William A Leone1, Ming Han Lincoln Liow1.   

Abstract

BACKGROUND: Currently, no serum metal ion threshold exists to identify adverse tissue reactions in total hip arthroplasty (THA) patients with taper corrosion. Our study aims to investigate the sensitivity and specificity of serum metal ions in detecting taper corrosion related pseudotumors in patients with dual taper modular THA.
METHODS: A total of 148 patients with dual taper modular THA were investigated: (1) 90 patients with pseudotumors detected with metal artifact reduction sequence-magnetic resonance imaging (MARS-MRI) and (2) 58 patients without pseudotumors on MARS-MRI. Receiver operating characteristic curves were constructed to determine the sensitivity and specificity using different metal ion thresholds. The severity of intraoperative tissue damage was correlated with preoperative metal ion levels.
RESULTS: Pseudotumor was associated with higher cobalt (5.0 μg/L vs 3.7 μg/L, P < .01) and Co/Cr ratio (6.0 vs 3.7, P < .01). The sensitivity and specificity for cobalt level of 2.8 μg/L and Co/Cr ratio of 3.8 in detecting taper corrosion-related pseudotumors on MARS-MRI was 88% and 32% and 70% and 50%, respectively. Higher intraoperative tissue damage grades demonstrated significantly higher Co/Cr ratios (8.6 vs 3.4, P = .03).
CONCLUSION: Although metal ion levels alone should not be relied on as the sole parameter to determine revision surgery, cobalt level >2.8 μg/L and the Co/Cr ratio >3.8 are useful clinical diagnostic adjuncts in the systematic clinical evaluation for taper corrosion-related adverse tissue reactions in patients with dual modular taper THA.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  dual taper modular stem; metal ion threshold; pseudotumor; receiver operating characteristics curve; taper corrosion; total hip arthroplasty

Mesh:

Substances:

Year:  2016        PMID: 27776907     DOI: 10.1016/j.arth.2016.08.040

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  7 in total

1.  Diagnosis of the failed total hip replacement.

Authors:  Adeel Aqil; Nikhil Shah
Journal:  J Clin Orthop Trauma       Date:  2019-12-03

2.  Outcome of revision surgery for adverse local tissue reactions in patients with recalled total hip arthroplasty.

Authors:  Christian Klemt; Sakkadech Limmahakhun; Georges Bounajem; Christopher M Melnic; Michael J Harvey; Young-Min Kwon
Journal:  Arch Orthop Trauma Surg       Date:  2021-04-09       Impact factor: 2.928

Review 3.  Lower limb joint repair and replacement: an overview.

Authors:  Rocco Aicale; Nicola Maffulli
Journal:  F1000Res       Date:  2019-12-19

4.  Adverse Tissue Reactions and Metal Ion Behavior After Small-Head Metasul Hip Arthroplasty: A Long-Term Follow-Up Study.

Authors:  Tsunehito Ishida; Toshiyuki Tateiwa; Yasuhito Takahashi; Yohei Nishikawa; Takaaki Shishido; Toshinori Masaoka; Kengo Yamamoto
Journal:  Orthop Surg       Date:  2021-12-15       Impact factor: 2.071

Review 5.  Imaging in Hip Arthroplasty Management Part 2: Postoperative Diagnostic Imaging Strategy.

Authors:  Charles Lombard; Pierre Gillet; Edouard Germain; Fatma Boubaker; Alain Blum; Pedro Augusto Gondim Teixeira; Romain Gillet
Journal:  J Clin Med       Date:  2022-07-29       Impact factor: 4.964

6.  Atypical Presentation of Periprosthetic Joint Infection With Pseudotumor With a Modular-Neck Stem Implant.

Authors:  Yonatan Schwartz; Daniel J Sherwood; Eli Kamara
Journal:  Cureus       Date:  2022-09-06

7.  Do Battlefield Injury-acquired Indwelling Metal Fragments Induce Metal Immunogenicity?

Authors:  Lauryn Samelko; Joseph Petfield; Kyron McAllister; Joseph Hsu; Michael Hawkinson; Joshua J Jacobs; Nadim J Hallab
Journal:  Clin Orthop Relat Res       Date:  2020-04       Impact factor: 4.755

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.